Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Yukimasa Shiotsu

Shiro Akinaga

Chikara Murakata

Shiro Soga

Yutaka Kanda

Tatsuya Tamaoki

Shinji Nara

Fumihiko Kanai

Yutaka Saitoh

Masami Okabe

Nobuyoshi Amishiro

Tomoki Naoe

Hitoshi Kiyoi

Yoji Ino

Takayuki Nakashima

Harumi Ogawa

Mayumi Miyata

Tadakazu Akiyama

Takako Shiraki

Hiroshi Nakagawa

Jiro Kajita

Hiroshi Umehara

Yoshihisa Ohta

Kinya Yamashita

Jun-ichi Saito

Keiko Kawashima

Hiromi Ando

Motoki Miyama

Junichi Watanabe

Motoo Yamasaki

Yoshinori Yamashita

Yutaka Saito

Kazuhisa Uchida

Hideharu Anazawa

Hitoshi Arai

Haruhiko Yokoi

Yoko Kato

Yushi Kitamura

Tsutomu Matsumura

Hiroshi Ishida

Noboru Konishi

Koji Hagihara

Rieko Nakatsu

Takako Iida

Syoichi Isami

Yoji Ikuina

Nana Oiwa

The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): [wherein &#x2014;X&#x2014;Y&#x2014;Z&#x2014; represents &#x2014;O&#x2014;CR&#x2550;N&#x2014; (wherein Rrepresents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, Rrepresents &#x2014;NRR(wherein Rand Rmay be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like) and the like, Rrepresents &#x2014;NRR(wherein Rand Rmay be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)] or a pharmaceutically acceptable salt thereof.

Pyrimidine derivative compound

The present invention provides a compound represented by Formula (I): [wherein Rrepresents CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like,Rrepresents a hydrogen atom, CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

Indazole derivatives

The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONRRor the like; Rrepresents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; Rand R, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and Rand R, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

Hsp90 family protein inhibitors

(wherein n is an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic-alkyl, substituted or unsubstituted aryl, &#x2014;CONRR, &#x2014;NRR, etc.; Rrepresents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; Rand Rmay be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; Rand Rmay be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, etc.) Provided are an Hsp90 family protein inhibitor comprising, as an active ingredient, a benzene derivative of formula (I) or a prodrug thereof or a pharmaceutically-acceptable salt thereof, etc.

The present invention provides a compound represented by Formula (I): [wherein Rrepresents CONRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or Rand Rare combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like,

The present invention relates to a fusion polypeptide which comprises a polypeptide having G-CSF activity and a polypeptide having TPO activity and DNA which codes for the fusion polypeptide, to a fusion polypeptide in which a polypeptide having G-CSF activity and a polypeptide having TPO activity are fused via a spacer peptide and DNA which codes for the fusion polypeptide and to a polypeptide in which the fusion polypeptide comprising a polypeptide having G-CSF activity and a polypeptide having TPO activity is chemically modified with a polyalkylene glycol derivative. It also relates to an anemia-treating composition containing the fusion polypeptide as an active ingredient.

hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same

Radicicol derivatives

Radioicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof:

Radicicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof:

Alkyl and aralkyl-substituted pyrrolocarbazole derivatives that

The present invention relates to therapeutic agents for thrombocytopenia which contain an indolocarbazole derivative represented by the formula (I) given below or a pharmaceutically acceptable salt thereof as an active ingredient, and to novel indolocarbazole derivatives. ##STR1##

Indolocarbazole derivatives and therapeutic method for stimulating

The present invention provides a method of treating thrombocytopenia, which comprises administering to a patient suffering from thrombocytopenia, an effective amount of an indolocarbazole derivative represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group or a tetrahydropyranyl group; R.sup.2A and R.sup.3A, which may be the same or different, each represent a hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a substituted or unsubstituted aralkyl group or a monosaccharide residue where a hydroxyl group at the anomer position is removed; R.sup.4A and R.sup.5A, which may be the same or different, each represent a hydrogen atom, a formyl group, a hydroxyl group or a halogen atom; W.sup.A1 and W.sup.A2 represent hydrogen atoms or are combined together to form an oxygen atom; and X.sup.A1 and X.sup.A2 represents two hydrogen atoms or are combined together to form a single bond, provided that when X.sup.A forms a single bond, then R.sup.1, R.sup.2A, R.sup.3A, R.sup.4A, R.sup.5A, and W.sup.A do not simultaneously represent a hydrogen atom, or a pharmaceutically acceptable salt.

Therapeutic agent for thrombocytopenia and indolocarbazole derivatives

Disclosed is an indolocarbazole derivative represented by the following formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## [wherein R.sup.1 represents substituted or unsubstituted lower alkyl, R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, R.sup.3 and R.sup.4 are the same or different, and represent hydrogen, nitro, NR.sup.5 R.sup.6, OR.sup.9, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, or CH.dbd.NNR.sup.10 R.sup.11, W represents two hydrogen atoms or oxygen, and Me represents methyl, provided that when R.sup.1 is unsubstituted lower alkyl, R.sup.3 and R.sup.4 are not simultaneously hydrogen.

Indolocarbazole derivatives that stimulate platelet production

Growing community of inventors

Sunto-gun, Japan

Yukimasa Shiotsu